




RealRate

PHARMACEUTICAL 2021

VYNE Therapeutics Inc.
Rank 399 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

VYNE Therapeutics Inc.
Rank 399 of 409



The relative strengths and weaknesses of VYNE Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 174% points. The greatest weakness of VYNE Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 829% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,333%, being 978% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	87,259
Cost of Goods Sold	1,392
Intangible Assets	0
Liabilities, Current	21,453
Liabilities, Non-Current	34,796
Other Assets	5,928
Other Compr. Net Income	-5.0
Other Expenses	141,811
Other Liabilities	0
Other Net Income	-1,110
Property and Equipment	555
Research and Development	43,533
Revenues	20,993
Selling, General and Administrative Expense	89,543

Output Variable	Value in 1000 USD
Assets	93,742
Liabilities	56,249
Expenses	276,279
Stockholders Equity	37,493
Net Income	-256,396
Comprehensive Net Income	-256,398
Economic Capital Ratio	-1,333%

